Lenalidomide after remission for rare lymphoma in the brain/eye
Part of Brain & nervous system, Cancer, Eyes & vision clinical trials.
This trial studies whether lenalidomide maintenance (ongoing pill treatment after remission) can help prevent relapse in people with primary central nervous system lymphoma or primary eye lymphoma. It’s aimed at adults who already completed standard chemo and radiation and are now in a complete or partial response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18+) with confirmed lymphoma in the brain and/or eye
- You finished standard remission treatment (chemo with high-dose methotrexate, then reduced-dose whole brain radiation) and are in complete or partial response
- You can safely do required procedures like MRI scans and taking fluid samples from the spine and/or eye (lumbar puncture/Omaya tap)
- Your blood counts and key organs (heart, lungs, liver, kidneys, thyroid) are working well enough for treatment
- You can take pills by mouth and agree to required study visits and tests, including MRI and fluid sampling
- If you can get pregnant, you must do two recent negative pregnancy tests and use effective birth control; if you’re male and your partner can get pregnant, you must use effective barrier contraception during the study and for 28 days after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies lenalidomide taken after your first treatment has worked for primary central nervous system lymphoma (PCNSL). It aims to help keep the lymphoma from coming back by testing lenalidomide as ongoing “maintenance” treatment.
This trial studies whether lenalidomide and rituximab can help keep primary CNS lymphoma from coming back after initial chemotherapy. It may be an option if you cannot do a transplant and you can take pills.
This Phase 1 trial tests adding two cancer medicines—lenalidomide and nivolumab—to the usual treatment for primary CNS diffuse large B-cell lymphoma (a type of lymphoma in the brain/spinal fluid). The goal is to see if the combination is safe and if it works better than the usual approach.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
This trial tests whether a maintenance therapy with rituximab (a targeted antibody) can help prevent relapse after initial treatment with lenalidomide and rituximab (R2) in people with newly diagnosed marginal zone lymphoma who cannot have standard chemotherapy.
Hear when a new Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.